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Objectives. We attempted to investigate the relation between
patient characteristics and adverse outcome in patients with
ischemia and clinically stable coronary artery disease (CAD).
Background. Evidence suggests that cardiac ischemia, detected
by exercise stress testing (ETT) and ambulatory electrocardio-
graphic (AECG) monitoring during daily living, identifies a
subgroup of patients at increased risk for adverse outcome, but
the relation between these ischemia findings and clinical and
angiographic characteristics is largely unknown.
Methods. We examined the relation between clinical, angio-
graphic and ischemia characteristics at entry with adverse out-
come observed at 1 year in the 558 patients enrolled in the
Asymptomatic Cardiac Ischemia Pilot (ACIP) study.
Results. By the 12-month visit 13.1% of patients had an
ischemia-related adverse clinical outcome that included death,
nonfatal myocardial infarction or an ischemia-related hospital
admission. Multivariate analysis identified only the number of
AECG ischemic episodes at entry (odds ratio [OR] 1.06, 99%
confidence interval [CI] 1.01 to 1.12, p 5 0.002) as an independent
predictor of outcome. Assignment to revascularization (as op-
posed to an initial medical treatment strategy) showed a trend
(OR 0.56, 99% CI 0.26 to 1.2, p 5 0.05). None of the other baseline
clinical, exercise or angiographic variables examined provided
additional information relative to adverse outcome.
Conclusions. Determinants of adverse outcome, among clini-
cally stable patients with CAD and ischemia induced by stress and
daily life were magnitude of AECG ischemia before treatment and,
possibly, initial treatment assignment. Among the many other
characteristics examined, including age, symptom status and
angiographic and exercise variables, none contributed additional
independent prognostic information. These two simple variables,
which may be modifiable, need further study in a larger trial.
(J Am Coll Cardiol 1997;29:1483–9)
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Management of clinically stable patients with coronary artery
disease (CAD) remains an important challenge. This is, in
part, related to the relatively low rate of adverse outcome in
this patient group and the, at best, relatively modest potential
benefit from specific therapies. Thus, clinicians search for
predictors of adverse outcome to enhance the possibility of
improving outcome in patients judged to be at highest risk.
Although ischemia during stress testing has long been linked
with prognosis, considerable recent evidence (1–20) suggests
that cardiac ischemia during daily living, detected by ambula-
tory electrocardiographic (AECG) monitoring, identifies in-
creased risk for adverse outcome. However, the precise rela-
tion between clinical, coronary angiographic, exercise treadmill
test (ETT) and AECG ischemic findings and subsequent
ischemia-related adverse outcome has not been clearly de-
fined. Published data are limited by small sample size, lack of
prospective protocol design, selection biases associated with
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heterogenous clinical presentations and physician-assigned
rather than randomly assigned treatment and lack of core
laboratory readings of tests for ischemia and angiograms.
We hypothesized that ischemia findings would interact
with clinical and angiographic findings to determine outcome.
Accordingly, we investigated the relation of clinical, coronary
angiographic and cardiac ischemia findings at entry with
ischemia-related adverse outcome during follow-up in patients
enrolled in the Asymptomatic Cardiac Ischemia Pilot (ACIP)
study.
Methods
Overview of ACIP project. The ACIP study design, patient
characteristics and treatment outcomes are reported in detail
elsewhere (21–23). Briefly, this trial, sponsored by the National
Heart, Lung, and Blood Institute, investigated three different
randomly assigned initial treatment strategies in clinically
stable patients with CAD amenable to revascularization and
stress-induced and daily life ischemia as assessed by AECG.
The treatment strategies were angina-guided medical therapy,
AECG ischemia–guided medical therapy and revasculariza-
tion. Medical therapy consisted of two drug combinations (i.e.,
atenolol and nifedipine or diltiazem and isosorbide dinitrate),
which were randomly assigned except when prohibited by the
clinical condition (e.g., postmyocardial infarction prophylaxis).
Revascularization consisted of either percutaneous translumi-
nal coronary angioplasty or coronary artery bypass graft sur-
gery, as determined by the site investigator. A total of 558
patients were entered into the study at 10 sites and evaluated
for treatment-related effects on ischemia-related adverse out-
come at predetermined time periods after study entry. Stan-
dardized forms were used to collect information about clinical
characteristics, coronary anatomy and ischemia at study entry
(qualifying visit [QV]) and outcome at follow-up visits. These
forms were completed by a site study nurse or physician-
investigator at scheduled visits or clinically indicated interim
visits throughout the follow-up period. Coronary angiograms,
AECGs, electrocardiograms (ECGs) and ETT ECGs were
each read at three respective core laboratories. Investigators
did not know the AECG or core laboratory findings. Core
laboratory personnel did not know the clinical outcome or
other core laboratory findings as each core laboratory had
access only to the results that they generated in each case.
Outcomes of analyses. Analyses were conducted to inves-
tigate the hypothesis that patient characteristics at entry would
interact to determine the presence of an ischemia-related
adverse outcome during follow-up. The analyses conducted
used ACIP secondary outcome variables consisting of
ischemia-related clinical events that occurred by 1 year. The
events included in this definition were death, nonfatal myocar-
dial infarction and ischemia-related hospital admissions. These
ischemia-related events were defined by the independent Mor-
tality and Morbidity Classification Committee (MMCC) after
review of all available patient-related documents (e.g., hospital
records, ECGs, cardiac enzyme levels). The adjudicated
ischemia-related hospital admissions were used to express
clinically important ischemia-related events, in addition to
cardiac death and nonfatal myocardial infarction, and to
eliminate physician-directed nonprotocol revascularization
procedures and hospital admissions that may have occurred
without an antecedent exacerbation in ischemia. In these
analyses, patients experiencing multiple events were tabulated
according to a hierarchy so that only the most serious event
was tabulated. The following order was used: death . nonfatal
myocardial infarction . ischemia-related hospital admission.
Statistical analyses. The demographic and other informa-
tion on patient characteristics obtained at entry were analyzed
for associations with ischemia-related adverse outcome as
defined before with the use of univariate Cox regression
analysis. All characteristics found by univariate analysis at p ,
0.1 were then included in the stepwise multivariate Cox
regression analysis. Odds ratios (OR) and 99% confidence
intervals (CI) were calculated for both the univariate and
multivariate models. The p values were calculated by using
chi-square, Mantel-Haenszel or Student t tests as appropriate.
A priori, for all multigroup comparisons, a p value of , 0.01
was taken to indicate statistical significance for all the ACIP
analyses (23,24).
Results
Baseline characteristics and adverse outcomes. Entry char-
acteristics (at QV). As previously reported (21–23), the ACIP
patients were clinically stable, and principally elderly (mean
age 61.4 years), male (85.8%) and white (85.7%). Although
70.1% had reported angina either within 6 weeks of entry or
induced during a study ETT or AECG, most (75.6%) had
multivessel CAD, proximal coronary artery stenosis $50%
(63.6%) and angiographic evidence for complex plaque
(53.9%). These coronary angiographic findings were recently
published in detail (25). An ejection fraction $50% was
present in 88.9%. The majority had a normal 12-lead rest ECG
and, although patients with $1-mm ST segment depression at
entry were excluded by protocol, 23.7% had negligible or
minor (#0.09-mm) ST segment changes on the entry ECG.
The mean number of ischemic episodes for the 48-h AECG
monitoring period was 4.9 6 5.3 (median 3) and the mean
Abbreviations and Acronyms
ACIP 5 Asymptomatic Cardiac Ischemia Pilot study
AECG 5 ambulatory electrocardiogram, ambulatory
electrocardiographic
CAD 5 coronary artery disease
CI 5 confidence interval
ECG 5 electrocardiogram, electrocardiographic
ETT 5 exercise treadmill 1 exercise stress test
MMCC 5 Mortality and Morbidity Classification Committee
OR 5 odds ratio
QV 5 qualifying visit
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duration of these episodes was 42.9 6 57.9 (median 22) min.
The mean total exercise time using the ACIP study ETT
protocol was 6.8 6 3.2 min, and 83.1 6 11.8% of patients
achieved their age-predicted heart rate. The mean maximal ST
segment depression during exercise was 2.4 6 1.0 mm. The
protocol permitted an alternate stress test that documented
ischemia in the 10 patients who could not exercise.
Clinical outcomes. The frequencies (by number and per-
cent) of ischemia-related adverse events observed by 1 year are
summarized in Table 1 according to treatment strategy and for
all patients. The adverse events included only death, nonfatal
myocardial infarction and MMCC-adjudicated ischemia-
related hospital admissions, and a total of 73 patients (13.1%)
had at least one event by 1 year. Eleven patients died from
cardiac causes, 21 had a nonfatal myocardial infarction and 41
were admitted to the hospital for other ischemia-related
events.
Relation between baseline characteristics and adverse out-
come. Univariate analysis. The patient entry characteristics
associated with the presence (73 patients) or absence (485
patients) of adverse outcome events by 1 year are summarized
in Table 2. Among ischemia characteristics, total exercise time
at entry on the QV ETT (OR 0.88, 99% CI 0.78 to 0.99, p 5
0.006) was associated with adverse outcome, and trends were
noted for proximal left anterior descending coronary artery
stenosis .50% (OR 1.79, 99% CI 0.93 to 3.45, p 5 0.02),
number of ischemic episodes (OR 1.03, 99% CI 1.00 to 1.07,
p 5 0.02) and duration of ischemic episodes (OR 1.03, 99% CI
1.03 to 1.07, p 5 0.03) on the QV AECG. None of the other
clinical or angiographic findings at entry that we examined
were associated with adverse outcome in this univariate anal-
ysis.
Multivariate analysis. Stepwise multivariate Cox regression
analysis identified only the number of ischemic episodes at
entry on the QV AECG (OR 1.06, 99% CI 1.01 to 1.12, p 5
0.002) as a significant independent predictor of adverse out-
come (Table 3). A trend (p 5 0.05) was noted for initial
revascularization strategy treatment assignment as compared
with the angina-guided medical treatment strategy. No other
variables examined contributed additional information relative
to outcome. The risks for adverse outcome by 1 year associated
with increasing AECG ischemia at entry are illustrated in
Figure 1.
Discussion
Our findings confirm that ischemia during daily life, as
assessed by AECG, can be used to identify a group of patients
with CAD who are at relatively high risk for adverse ischemia-
related outcome among those who appear to be otherwise
clinically stable. By 1 year, among the patients assigned to all
three treatment strategies (Table 1), 13% had died, had a
nonfatal myocardial infarction or had been admitted to the
hospital because of an ischemic event. Among patients as-
signed an initial medical treatment strategy, the adverse out-
come rates were even higher: 15% for death, nonfatal myocar-
dial infarction or hospital admission for an ischemic event and
7.9% for only death or nonfatal myocardial infarction. Al-












No. % No. % No. % No. %
By 1 year
Any ischemic event 29 15.9 25 13.7 19 9.9 73 13.1
Death 8 3 0 11
Nonfatal MI 8 8 5 21
Ischemia-related hospital admission* 13 14 14 41
Details of clinical events and
combinations
Death, MI, CABG 0 1 0 1
Death, MI 2 0 0 2
Death, CABG 1 0 0 1
Death, PTCA 1 0 0 1
Death 4 2 0 6
MI, CABG, PTCA 1 0 0 1
MI, CABG 5 7 2 14
MI, PTCA 1 1 1 3
MI 1 0 2 3
Ischemic event,* PTCA, CABG 1 3 0 4
Ischemic event,* CABG 3 7 3 13
Ischemic event,* PTCA 4 3 4 11
Ischemic event* 5 1 7 13
*Ischemia-related hospital admission classified by the Mortality and Morbidity Classification Committee as due to exacerbation of ischemia and tabulated as an
ischemic event. CABG 5 coronary artery bypass graft surgery; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty.
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Table 2. Baseline Characteristics and Clinical Outcome: Univariate Analysis
Death, MI or Ischemia-Related Hospital
Admission by 365 Days
No (n 5 485) Yes (n 5 73) Univariate Cox Regression
No. % No. % Odds Ratio 99% CI p Value
Age (yr) (mean 6 SD) 61.5 6 8.2 61.2 6 9.3 0.96 0.67–1.38 0.76
$60 yr 299 61.7 44 60.3 0.95 0.52–1.77 0.84
Men 417 86.0 62 84.9 0.93 0.40–2.16 0.83
White 418 86.2 60 82.2 0.76 0.34–1.66 0.36
Symptoms: angina (within 6 wk of entry or
on QV ETT or other stress test or with
EPI on QV AECG)
331 68.3 60 82.2 2.06 0.94–4.54 0.08
Drug regimen
Atenolol/nifedipine 242 49.9 42 57.5
Diltiazem/isosorbide dinitrate 243 50.1 31 42.5 0.75 0.41–1.39 0.22
History
Previous MI 202 41.7 24 32.9 0.71 0.37–1.34 0.16
Diabetes 76 15.7 14 19.2 1.26 0.59–2.71 0.44
Heart failure 15 3.1 1 1.4 0.44 0.03–5.94 0.42
Peripheral vascular disease 33 6.8 5 6.9 0.98 0.30–3.24 0.97
Hypertension 184 37.9 25 34.3 0.88 0.46–1.66 0.59
Current smoker 78 16.3 12 16.4 1.00 0.44–2.26 0.99
Ever smoked 317 65.4 49 67.1 1.07 0.57–2.04 0.78
Previous PTCA 85 17.5 15 20.6 1.21 0.58–2.56 0.51
Previous CABG 27 5.6 4 5.5 0.98 0.26–3.72 0.98
Previous PTCA or CABG, or both 107 22.1 19 26.0 1.24 0.62–2.46 0.43
Family history of CAD ,55 yr 195 40.2 36 49.3 1.39 0.76–2.54 0.16
Physical examination (mean 6 SD)
SBP (mm Hg) 138.4 6 19.1 142.2 6 21.5 1.10 0.94–1.29 0.11
DBP (mm Hg) 79.5 6 9.9 79.1 6 10.7 0.97 0.71–1.32 0.78
HR (beats/min) 69.3 6 11.8 69.3 6 11.3 1.00 0.77–1.29 0.99
Coronary angiography (stenosis $50%) 1.13 0.76–1.67 0.43
1 vessel 120 24.7 16 21.9 1.00
2 vessel 185 38.1 26 35.6 1.05 0.47–2.39 0.87
3 vessel 180 37.1 31 42.5 1.26 0.57–2.77 0.46
Proximal stenosis $50% 301 62.3 52 72.2 1.51 0.77–2.97 0.12
Proximal LAD stenosis $50% 155 32.1 33 458 1.79 0.93–3.45 0.02
Proximal stenosis $70% 192 39.8 35 48.6 1.41 0.77–2.60 0.14
Definite complex plaque 166 36.9 26 37.7 1.04 0.55–1.99 0.88
Definite or probable complex plaque 245 54.5 35 50.7 0.88 0.47–1.63 0.59
Ejection fraction
,35% 7 1.5 1 1.5 0.83 0.06–11.28 0.85
35% to 49% 45 9.8 6 8.7 0.87 0.28–2.70 0.75
50% to 64% 204 44.3 27 39.1 0.84 0.43–1.63 0.50
$65% 205 44.5 35 50.7 1.00
Not available 24 4
by 10% unit 1.05 0.76–1.44 0.70
QV rest 12-lead ECG
Abnormal 229 47.2 42 57.5 1.46 0.80–2.69 0.11
Q waves 58 12.0 10 13.7 1.15 0.48–2.79 0.66
ST depression ,0.1 mm 108 22.3 24 32.9 1.66 0.87–3.15 0.04
T wave abnormalities 145 29.9 25 34.3 1.20 0.63–2.26 0.47
QV AECG (mean 6 SD)
No. of EPIs 4.7 6 5.0 6.2 6 6.6 1.03 1.00–1.07 0.02
Duration of EPIs 40.8 6 50.5 56.4 6 92.7 1.03 1.00–1.07 0.03
HR change (max 2 mean) 56.4 6 14.8 54.5 6 15.3 0.92 0.74–1.14 0.30
QV ETT (mean 6 SD)
Total exercise time 7.0 6 3.2 5.8 6 2.8 0.88 0.78–0.99 0.006
Final HR 132.0 6 18.8 130.3 6 19.3 0.96 0.82–1.13 0.51
% age-predicted HR 83.3 6 11.9 82.0 6 11.6 0.92 0.72–1.19 0.43
Max ST depression 2.4 6 1.0 2.5 6 1.1 1.08 0.81–1.45 0.48
For the continuous variables ischemic episode (EPI) on qualifying visit ambulatory electrocardiogram (QV AECG) and total exercise time, the odds ratio
corresponds to a 1-unit increase; for all other continuous variables (age, systolic blood pressure [SBP], diastolic blood pressure [DBP], heart rate [HR], ejection fraction,
duration of ischemia, heart rate change, final heart rate, % age-predicted heart rate) the odds ratio corresponds to a 10-unit increase. CAD 5 coronary artery disease;
CI 5 confidence interval; ETT 5 Asymptomatic Cardiac Ischemia Pilot study protocol exercise treadmill 1 stress test; LAD 5 left anterior descending coronary artery;
other abbreviations as in Table 1.
though most previous reports (1–20) have suggested that
AECG ischemia predicts a higher rate of adverse outcome
than that of patients without AECG ischemia, some reports
(24,26,27) have not. However, the three latter reports are
limited by relatively small sample size, single-center and ret-
rospective design selection bias, very low risk subjects and
different inclusion criteria. None used ACIP entry criteria or
addressed the relative predictive value and potential confound-
ing of the historical, ischemic (both ETT and AECG) and
angiographic data by using multiple centers, common proto-
cols and core laboratory readings.
Clinical implications. Results of this analysis suggest that
the magnitude of AECG ischemia before treatment and,
perhaps, initial medical treatment (as opposed to initial
revascularization) are independent predictors of subsequent
increased risk for ischemia-related adverse outcome. This
conclusion is limited to clinically stable patients with revascu-
larizable CAD and ischemia during both stress testing and
daily life as assessed by AECG. These findings imply that,
given two patients assigned to the same medical therapy, an
increase of one AECG episode of ischemia at entry will be
associated with an increase in risk for clinical adverse outcome
(i.e., cardiac death, myocardial infarction or hospital admission
for an ischemic event) at 1 year of ;5% to ;10% with a
remarkably narrow 99% CI (Fig. 1). Conversely, in similar
patients with AECG ischemia at entry, initial revascularization
(as opposed to initial medical therapy) is likely to be associated
with an ;45% reduction in risk for clinical adverse outcome
(Table 3).
Link between ischemia and adverse outcome. These results
advance our understanding of the link between the magnitude
of risk and AECG-detected ischemia occurring during daily
life that has been suggested elsewhere (1–20). The precise
amount of AECG ischemia at which an increased risk for
adverse outcome may begin (i.e., threshold) has not yet been
defined. In the ACIP study we used an arbitrary definition of
abnormality based on ST segment deviation of 1.0 mm with a
duration $1.0 min. This definition was chosen in earlier studies
(28,29) of AECG monitoring for ischemia, largely to circum-
vent various artifactual and biologic variations in the ST
segment level that may occur throughout the day and may not
be of ischemic origin. When studying patients with well defined
CAD and stress-induced ischemia such as those in the ACIP
study, where other variations of ST segments have been
excluded or minimized, it seems appropriate to explore other
definitions of ST segment depression (e.g., ,1.0-min duration
and ,1.0 mm-deviation). Such an analysis could identify the
threshold value at which the ST segment depression level or
duration reached during daily life is associated with increased
risk for adverse outcome. This could be important to better
define those CAD patients at increased risk and, perhaps, those
with a suggested reduction in risk imparted by appropriate
therapy (8–10,13,20,23). Little attention has been given to this
low cost, simple and easily obtained marker of increased risk in
relation to clinical findings. The current results provide compel-
ling data to confirm that a greater number of ischemic episodes is
directly related to greater risk for adverse outcome (Fig. 1).
The precise mechanism by which daily life ischemia de-
tected by AECG monitoring is linked to adverse outcome is
unknown, but this ischemia probably represents a marker for
patients with functionally more severe and unstable CAD (e.g.,
endothelial dysfunction, microthrombi, plaque fissuring). Pre-
vious reports (14,20) have indicated that the association be-
tween AECG ischemia and adverse outcome appears strongest
in patients presenting with clinical findings of an acute isch-
emic syndrome such as unstable angina or postinfarction
ischemia. Such patients often have unstable, complex coronary
lesions, and such pathologic findings have a direct relation to
recurrent ischemia on AECG monitoring and to adverse
outcome (19,20). The ACIP study of patients with clinically
stable CAD and daily life ischemia detected on AECG moni-
toring and abnormal ETT findings also revealed a high risk for
adverse outcome that was related to AECG ischemia. Angio-
graphic data from the ACIP core laboratory also indicate that
the majority of these patients with daily life ischemia had
definite or possible complex coronary plaques, as well as
proximal coronary lesions at angiography (25). However, even
Figure 1. Relation between risk of adverse outcome at 1-year
follow-up and magnitude of ischemia at entry. Plot of excess risk
(circles) (OR 2 1 3 100%) and 99% CI (triangles) for clinical
outcome by number of AECG ischemic episodes recorded at entry.







Death, myocardial infarction or
hospital admission†
Ischemia-guided medical strategy‡ 0.80 0.39–1.61 0.41
Revascularization strategy‡ 0.56 0.26–1.2 0.05
AECG ischemia (QV EPI§) 1.06 1.01–1.12 0.002
*Multivariate stepwise Cox regression odds ratios, 99% confidence interval
(CI) and p values. †Ischemia-related hospital admission classified by Mortality
and Morbidity Classification Committee. ‡Odds ratio as compared with the
angina-guided medical treatment strategy. §Odds ratio for increase of one
episode of ischemia (EPI) per 48 h of monitoring at entry on the qualifying visit
ambulatory electrocardiogram (QV AECG).
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proximal stenosis $70% did not achieve statistical significance
in the univariate analysis. Of all ACIP patients, ;30% were
asymptomatic and the remainder had mild, stable angina
during the 6 weeks before study entry. Although the presence
of symptoms, as assessed by the ACIP definition, showed a
slight trend suggesting an association with outcome in the
univariate analysis, it was not predictive of adverse clinical
outcome in the multivariate analysis. These findings support
the view that the clinical distinction between patients with
biologically stable CAD and those with unstable disease is
often unreliable when based on symptoms alone. It seems that
a subgroup of patients who appear to be clinically stable are at
relatively high risk for an adverse outcome because they have
“biologically unstable CAD,” as characterized by ulcerated
coronary plaques, acute thrombus formation and endothelial
dysfunction. Thus, ischemia detected by AECG monitoring
may be a simple, readily obtainable marker for patients with
more severe, complex and active CAD (30).
Traditional clinical risk factors. In this analysis the AECG
ischemic findings overwhelmed traditional risk factors for
CAD adverse outcome, such as age, hypertension, smoking,
prior myocardial infarction and family history. Even the extent
of CAD by angiography and ejection fraction was not predic-
tive of adverse outcome in this group with predominantly
multivessel CAD. Of the various angiographic and ETT vari-
ables examined, some were predictive in the univariate model,
but none were predictive in the multivariate model, supporting
the suggestion that most of the useful predictive information
was contained in the AECG data. These findings, along with
those recently reported by Gill et al. (16) and the ease of use
and low cost of AECG, add support for further studies
assessing AECG ischemia in patients with CAD. If our findings
can be confirmed in a larger trial over a longer period of time,
using only death and myocardial infarction as outcomes, they
could have an important impact on the utilization of more
expensive tests in the evaluation of patients with known CAD
and ischemia.
The lack of association of coronary angiographic variables
with ischemia-related adverse outcome deserves additional
comments. This observation emphasizes the limitations of
coronary angiograms used alone to assess the overall func-
tional and prognostic importance of the atherosclerotic disease
process. However, our results should not necessarily lead to
the conclusion that coronary angiographic variables are not
related to adverse outcome in other patient cohorts. Although
the ACIP patient inclusion criteria were broad, the need for
both abnormal ETT and AECG findings selected a group in
which the overall burden of ischemia resulted in a relatively
high risk for adverse clinical outcome. The current findings
suggest that in such a group, the presence of single-vessel
disease (defined by .50% coronary artery obstruction at
angiography) identified patients just as likely to have an
adverse outcome as those with double- or triple-vessel disease
(defined by .50% stenosis in two or three vessels). Thus, in
patients with ischemia during ETT and daily living, the CAD is
functionally severe and likely to be important in terms of
adverse outcome. Attempts to further quantify risk for adverse
outcome based on conventional angiographic criteria do not
contribute additional information related to this already high
risk.
Study limitations. This study has some limitations worthy
of discussion. First, these results are from a pilot study with a
relatively small sample size and only 1 year of follow-up.
Nevertheless, it is the largest study yet reported on ischemia
detected during daily life in clinically stable patients. Second,
we were able to adjust for only a specific number of patient
factors present at study entry. Some clinical factors not in-
cluded in these analyses may be important, specifically those
providing additional anatomic or physiologic information. Al-
though our analysis included many clinical, ECG and angio-
graphic variables, further analysis of symptoms or other mea-
surements, such as minimal lumen diameter, jeopardy scores
and territory at risk, intracoronary ultrasound or angioscopy-
derived intimal plaque characteristics, heart rate variability or
time of ST segment recovery, might be useful. Third, the
medical therapy was not used at maximal doses and was limited
to only two drug combinations (23). It is possible that addi-
tional doses or other combinations would provide greater
suppression of AECG ischemia and ischemia-related events.
Nevertheless, we believe that the doses used in the ACIP study
are similar to the doses used in current clinical practice.
Conclusions. The determinants of adverse outcome in the
patient with clinically stable CAD and cardiac ischemia are
multiple. Our analysis demonstrates that a few simple baseline
variables, which may be readily obtainable and modifiable,
seem to contain most of the prognostic information. These
include the magnitude of ischemia detected by AECG at entry
and, possibly, initial treatment.
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